According to the latest report Global Patent Situation Analysis and Patent Layout Strategy in the BNCT Field completed by an authoritative institution in August, Chinese entities represented by Neuboron are gradually emerging as leaders in the technological innovation of Boron Neutron Capture Therapy (BNCT). They have jumped to the global top spot in both patent applications and authorizations, demonstrating the strong advantages and great potential of China’s BNCT development. Furthermore, the Chinese market has become a focal point for patent application competition among countries worldwide, indicating that China plays a key role in reshaping the global BNCT industry structure.
The report points out that the number of global patent applications in the BNCT field has shown a steady growth trend over the past 20 years. Particularly since 2016, BNCT technology has entered a period of rapid development, with explosive growth in patent applications, which reached a peak in 2022. Among these, the number of patent applications received by the China National Intellectual Property Administration (CNIPA) accounts for approximately 26.53% of the total. Especially in the past decade, China has become the primary driver of global patent growth, thanks to its large volume of patent applications and high-quality layout coverage.
Among all players, Neuboron's patent strength demonstrates an absolute leading advantage globally, ranking first in the industry. It holds nearly 800 published patent applications and 530 authorized patents, covering multiple sub-fields such as neutron generation systems, radiation shielding measurement, treatment control systems, and boron-containing drugs. This fully showcases its leading position in the R&D of BNCT treatment equipment and new drugs, marking China's rise in the new track of precision medicine.
In the current wave of technological revolution, patent strength is the "hard currency" for enterprises to firmly grasp core technologies and secure a high ground in development. It is also a crucial indicator of a country's scientific and technological innovation capabilities and international discourse power. Neuboron's global-leading BNCT patent layout is not only a strong proof of its own strength, but also represents another disruptive technological "business card" of China stepping onto the world stage.
Looking ahead, with further advancement in technological R&D and the continuous maturity of the industrial ecosystem, China is expected to maintain its leading advantage in the BNCT field and contribute more Chinese wisdom and solutions to global cancer treatment.
